Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Gladys E Sepulveda"'
Autor:
Gladys E Sepulveda, Jeffrey P. Nadler, Amalia Rodriguez-French, Judith Millard, Paul G Wannamaker, Arnaldo R Quinones, Glenda Gray, Jack Boghossian
Publikováno v:
Journal of acquired immune deficiency syndromes (1999). 35(1)
Poor tolerability is a major cause of nonadherence and treatment discontinuation with protease inhibitors (PIs). Gastrointestinal (GI) disturbances are often cited as affecting PI tolerability, but other adverse effects, such as those that affect pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0ad4e9aba69467eccd31818258bdd82
https://pubmed.ncbi.nlm.nih.gov/14707788
https://pubmed.ncbi.nlm.nih.gov/14707788
Autor:
Judy Johnson, Gladys E. Sepulveda, Jorge Santana, Nicholaos C. Bellos, Michael Sension, S. Diane Goodwin, Michael H. Ames, Edwin DeJesus
Publikováno v:
HIV clinical trials. 3(5)
To compare the efficacy (sustained virologic suppression) and safety/tolerability of a switch to lamivudine 300 mg once daily (QD) versus continued lamivudine 150 mg twice daily (BID) in virologically suppressed patients (HIV-1 RNA400 copies/mL foror
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37ebd710debe2b7ec94dfa0aab373d63
https://pubmed.ncbi.nlm.nih.gov/12407485
https://pubmed.ncbi.nlm.nih.gov/12407485
Autor:
Donna Mildvan, Michael Sension, Harold A. Kessler, Gladys E. Sepulveda, Stephen E. Follansbee, Nicholaos C. Bellos, Seth Hetherington, Judy Johnson
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 34(4)
Expanded access programs (EAPs) provide medication to patients with life-threatening, treatment-refractory illnesses before regulatory approval and allow the acquisition of safety information. A 2-part, multisite EAP to evaluate abacavir, a carbocycl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::336ae57bea832fb69f702cfcdc78d68b
https://pubmed.ncbi.nlm.nih.gov/11797183
https://pubmed.ncbi.nlm.nih.gov/11797183
Autor:
David M. Parenti, Susan Swindells, Nancy Schoellkopf, Robert L. Murphy, John C. Pottage, Joseph G. Jemsek, Dolores M. Peterson, Robert Grosso, Joseph J. Eron, Gladys E. Sepulveda, Nicholaos C. Bellos, Michael Stevens, Jim Esinhart, Bruce Rashbaum
Publikováno v:
AIDS (London, England). 14(11)
Comparison of stavudine (d4T), didanosine (ddI) and indinavir (IDV) with zidovudine (ZDV), lamivudine (3TC) and IDV in HIV-1 infected patients.Randomized, open-label.Fourteen HIV Clinical Research Centers.Two-hundred and five patients with less than
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da3f5704ba74c7cc85407798711530de
https://pubmed.ncbi.nlm.nih.gov/10983647
https://pubmed.ncbi.nlm.nih.gov/10983647
Autor:
Chris Tsoukas, W. Christopher Ehmann, Marc Rubin, Mary Ann Fallon, John Bartlett, Pamela L. Self, Victoria A. Johnson, Gladys E. Sepulveda, Sharon L. Benoit, Joseph B. Quinn
Publikováno v:
Annals of Internal Medicine. 125:161
Objective : To compare the safety and activity of lamivudine plus zidovudine with the safety and activity of zalcitabine plus zidovudine in patients with moderately advanced human immunodeficiency virus (HIV) infection who had received zidovudine. De
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c6600cd6559336605fdbee56faff8eb4
https://doi.org/10.7326/0003-4819-125-3-199608010-00001
https://doi.org/10.7326/0003-4819-125-3-199608010-00001